chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Small rash at site of the injection on L thigh (papular, on an erythematous base) beginning July 17. Was very itchy. Progressed to inflamed erythematous 2x2cm area with excoriations/scabs from scratching when I saw her in clinic on July 20. Patient was also experiencing fever at visit on 7/20, to 100.4 per parent report. Also feeling fussy with low appetite. No other symptoms (cough, rhinorrhea, vomiting, diarrhea, rash elsewhere).
*Although my reactions are listed under possible side effects, when I had the first dose of the 2-dose series, in addition to having a flu shot at the same time, I had absolutely no side effects.  Therefore, I am reporting these following side effects as an adverse reaction to me.  Within 12 hours: fever, horrible headache, pain in arm around injection site (phantom pain in opposite arm).  Within 24 hours, muscle and joint pain all over, extreme tiredness, chills, skin hurt all over to the touch (one of my old fibromyalgia symptoms, but I hadn't experienced that for years);    At 36 hours, still dealing with headache, arm pain around injection site and skin red and blotchy around the site, extreme tiredness continued.  72 hours: arm still painful.  From Day 4 pain gradually subsided (I had been taking Advil on the advice of the Walgreen's pharmacist, whose advice I had sought).  Itching (the healing process, I assume) began about day 6 and continued through day 9.  I hope I haven't wasted your time, but again, I experienced no symptoms at all with the previous 1st dose in October 2019, and I thought I should report my uncommon reaction with the 2nd dose.
Fever to 100% on day one, oscillating between 100% to 104 over next 4 days.  Experienced diarrhea on Day 1 and 2 and 4.  No prior history of fever or diarrea.  Rash on trunk on Day 6, diagnosed by doctor over phone as Rosolea. Someone do a google search and realize that Rosolea is highly correlated to MMRs.  Doesn't anyone care about the kids?  Or does Merk just need to make so much money they can continue to hire from the FDA/CDC and lobby the FDA/CDC at the same time?  Money matters the most to everyone right? ? I guess that's probably what does motivate 99% of the people out there. I just don't want my kid to be the 1% collateral damage!
Injection site reaction including redness, swelling and warm-to-touch. Self-resolved, only redness shows 1 week later.
laryngitis; upper respiratory flu; Initial information was received on 03-Feb-2022 regarding an unsolicited valid non-serious case received from a consumer.  This case involves Adult female patient who experienced laryngitis and upper respiratory flu while receiving vaccine Influenza Vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza VACCINE produced by unknown manufacturer (strength, formulation, dose route, batch number and expiry date: unknown) on an unknown administration site for prophylactic vaccination. Information on batch number was requested.   It was reported after getting the flu shot patient got sick with laryngitis for 10 days,also she was sick with upper respiratory flu (respiratory disorder) for 23 days in november (onset :unknown). It is unknown if the patient experienced any additional symptoms/events.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events (laryngitis, respiratory disorder).  At time of reporting, the outcome was Unknown for the event laryngitis and was Unknown for the event respiratory disorder.
Injection site soreness, swelling, redness and itching that has persisted since injection on 2/3/21. Taking tylenol as needed for soreness and have applied hydrocortisone cream to ease itching, redness and swelling.
Fever, chills, hives, redness, swelling at (L) deltoid/upper arm
Information has been received from a medical assistant concerning a 17 week old patient who was vaccinated with the first dose of ROTATEQ orally on an unspecified date. No adverse symptoms were reported. Additional information has been requested.
VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins); This non-serious spontaneous report with reference numbers 02197725 / 02197588 was received by partner on 05-JUL-2022 and forwarded on 06-JUL-2022 from a consumer.    The causal relationship between Vaxelis and the reported event "multiple doses of VAXELIS administered since temperature excursion" was assessed as not applicable due to the nature of the event.    Further information is expected.  FOLLOW-UP INFORMATION was received by a partner on 01-AUG-2022 and forwarded on 03-AUG-2022, from a HCP. The case is maintained as non-serious.  The reporter confirmed that there were no Adverse Events following Vaxelis administration to the patient.  Due to the nature of the event, the causality between the event "VAXELIS administered since temperature excursion above 8.5° (10 mins)/Previous temperature excursion on 12-APR-22 above 8°C (10 mins)" and Vaxelis remained not applicable.  For reference purposes this case is linked to MCM-003725, MCM-003726, MCM-003729, MCM-003734, MCM-003735, MCM-003737, MCM-003738, MCM-003739, MCM-003740, MCM-003741, MCM-003742, MCM-003743, MCM-003744, MCM-003747, MCM-003749, MCM-003751, MCM-003752, MCM-003753, MCM-003757, MCM-003759, MCM-003760, MCM-003761, MCM-003724, MCM-003766, MCM-003767, MCM-003769, MCM-003770, and MCM-003772, due to same reporter.  No further information is expected.
"felt uncomfortable"; "tight chest"; "chest pain as lung pain when deep breath''; only first dose received; This spontaneous case was reported by a patient and describes the occurrence of MALAISE ("felt uncomfortable"), CHEST DISCOMFORT ("tight chest"), PULMONARY PAIN ("chest pain as lung pain when deep breath'') and PRODUCT DOSE OMISSION ISSUE (only first dose received) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced MALAISE ("felt uncomfortable"), CHEST DISCOMFORT ("tight chest"), PULMONARY PAIN ("chest pain as lung pain when deep breath'') and PRODUCT DOSE OMISSION ISSUE (only first dose received). On 14-Apr-2021, MALAISE ("felt uncomfortable"), CHEST DISCOMFORT ("tight chest") and PULMONARY PAIN ("chest pain as lung pain when deep breath'') had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (only first dose received) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.       No concomitant medications were reported.  No treatment information was reported.
Red, tender, rigid, and dry injection site reaction. Patient was instructed to monitor injection site for about three more days, then return to pharmacy.
Blindness; This spontaneous case was reported by a consumer and describes the occurrence of BLINDNESS (Blindness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Not Provided) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BLINDNESS (Blindness) (seriousness criterion medically significant). At the time of the report, BLINDNESS (Blindness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided by the reporter. No treatment information was provided by the reporter.  Patient also reported "this temp" with no measurement or date given.  Based on the current available information, a causal relationship cannot be excluded. Further information is not expected as reporter refused to be contacted.   Reporter did not allow further contact; Sender's Comments: Based on the current available information, a causal relationship cannot be excluded. Further information is not expected as reporter refused to be contacted.
pt recvd vax & exp dizziness, severe diarrhea & profound weakness which lasted 12 hrs; treatment: none; pt recvd 2nd vax w/no complaints;
Large blisters across her stomach and hip and was diagnosed with shingles.; Information has been received from a lawyer regarding a case in litigation, concerning a female patient (pt) of unknown age. Information regarding the pt's concurrent conditions, medical history and concomitant medications was not provided.  On or around 16-OCT-2016, the pt was vaccinated with zoster vaccine live(ZOSTAVAX) (dose, route of administration, anatomical location, lot number and expiration date were not reported) for prevention of shingles (herpes zoster).   On an unspecified, reported as "shortly after receiving Defendants' Zostavax vaccine", the pt suffered large blisters across her stomach and hip and was diagnosed with shingles. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, she had sustained severe and permanent personal injuries, including but not limited to: serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. She also had suffered and incurred damages, including medical related expenses, the loss of accumulations; and other economic and non-economic damages as a result of these injuries.  By the time of this report, the patient had not recovered from shingles. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
Approx 5 Minutes post vaccination : Severe Headache lasting approx 10 minutes, slight throat tightening, acceleration of heart rate that lasted about 15 minutes but continued intermittently for the first day post vaccination. Leg pain (aching)  that lasted for 4 days. I struggled to think...as though I was in a fog ...for example it took me along time to think of an answer to a question I was asked. This lasted for 2 days. Severe tiredness 6 hours post vaccination, I slept for 2 hours then insomnia the first evening. Nausea beginning 6 hours post vaccination then rolling nausea that continued 6 days .
Second dose caused swollen lymph node under left armpit lasted 3 weeks. Third dose caused swollen lymph nodes on neck, not sure how long it will last this time
Patient walked out to waiting room after vaccination and stated she felt light headed. I suggested she sit down in a vacant chair next to me, which she promptly did. In the chair while seated, she had an episode of fainting/syncope with a brief jerking motion suggestive of seizure. Her pupils were dilated and fixed during the episode, as her eyes were open but she was not responding to verbal prompts. I signaled for nursing assistance and patient was moved from the chair safely to the floor, in a supine position. Juice boxes were given to patient in an attempt to increase her blood pressure. She drank two juice boxes and then immediately vomited three times. She was then moved back into an examination room where she laid down for 10 minutes and recovered. Her left arm is sore at the injection site.
Patient was given IM Benadryl  prior to receiving COVID -Moderna vaccine.  Patient began having mild itching at the Benadryl injection site and mild nasal irritation about 2 hours after the COVID vaccine was administered. She took more Benadryl about 5 hours later receiving the vaccine. She experienced flushing/redness of skin after bathing. She experienced itching all over her body throughout the night. She took another 50mg Benadryl around midnight that night.  She reports symptoms gradually resolved after taking Benadryl syrup for about 2 days after receiving the  vaccine.
This spontaneous report as received from an other health professional refers to an 89 years old female patient. The patient was vaccinated SC. with ZOSTAVAX (lot # 671901/0421AE), 0.65 ml) on 24-JUL-2012. No other co-suspects were reported. Concomitant medications included amoxicillin, carbidopa (+) levodopa, dicyclomine hydrochloride, lorazepam, phenytoin sodium and VOLTAREN transdermal gel. On 24-JUL-2012 the patient experienced swelling and hives in the throat and her tongue felt full which happened 3 hours after onset of therapy. There was no wheezing or facial swelling or respiratory distress. The patient went to Urgent Care and Family Center for an unspecified duration. The patient was treated with IM corticosteroids (unspecified) and phenyltoloxamine. The outcome of swelling and hives in the throat, tongue feel full and hives in throat was unknown. The relatedness for swelling and hives in the throat, tongue fell full and hives in throat was unknown for ZOSTAVAX. Additional information has been requested.
This spontaneous report as received from a other health professional refers to a multiple patients of unknown age. On unknown dates, the patients were vaccinated with improperly stored doses of PROQUAD for prophylaxis. Concomitant therapies included sterile diluent (STERILE DILUENT). No adverse event.; Sender's Comments: US-009507513-1708USA012451: Original Case : 1708USA012451.
This spontaneous report as received from a nurse practitioner refers to her currently 16 year old son. The patient's historical conditions included increased blood pressure when the patient received Ketamine as an anesthetic for unspecified procedure (in approximately 2000, when the patient was 2 years old). The patient also experienced, when he was in kindergarten, an meningitis after receiving a dose of DTAP vaccine (manufacturer unknown) and IPV (Described in MARRS # 1403USA003195).  The reporter stated that her twins boy and girl (captured in MARRS # 1403USA007226 experienced severe reactions after vaccination with booster dose of VARIVAX.  On an unknown date in 2008 the patient experienced very high fever (104 F), which persisted for 2 days and then subsided, generalized lymphadenopathy and neurologic symptoms which included repetitive motions and sensory issues where he could not tolerate any normal sound and became very sensitive to touch. These neurologic symptoms persisted for about 6 months. The outcome of generalized lymphadenopathy was not reported. The relatedness between events and VARIVAX was not reported. The reporter stated that her children were very sensitive to vaccines and she's been closely working with allergist and immunologist to find the cause of these reactions. This is one of three same patient cases from the same source (MARRS # 1403USA003195, 1403USA007225). This is one of several cases from the same source (MARRS 1403USA003195, 1403USA007255, 1403USA007226, 1403USA007227, 1403USA007228).  Additional information is not expected.
This case was reported by a consumer and described the occurrence of vaccination failure in a male patient who received BEXSERO. On an unknown date, the patient received BEXSERO at an unknown dose. On an unknown date, unknown after receiving BEXSERO, the patient experienced vaccination failure (serious criteria GSK medically significant) and meningitis (serious criteria death and GSK medically significant). On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the meningitis was fatal. The reported cause of death was meningitis. It was unknown if the reporter considered the vaccination failure and meningitis to be related to BEXSERO. Additional details were provided as follows: The reporter reported this case for his/her friend's boyfriend. The age at vaccination was not reported. The patient had contracted meningitis from after receiving BEXSERO and died. This case was considered as suspected vaccination failure since the completion of vaccination schedule, time to onset of event and confirmatory laboratory test were unknown.
Patient experienced a high fever of 101.3F, body aches, chills and headache after receiving TD booster shot.  Called the physician's office and was advised to take MOTRIN.  Follow up on 06/16/08: Patient had a fever for two days.  Patient recovered.
Gave pediatric pfizer dose to adult. No signs or symptoms of distress or adverse reactions noted. Client stated felt fine.
Large/big hives on both arms; This case was reported by a consumer via call center representative and described the occurrence of hives in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th October 2022, the patient received the 1st dose of Shingrix. In October 2022, 6 days after receiving Shingrix, the patient experienced hives. The patient was treated with steroids nos (Steroid (Not Specified)). On an unknown date, the outcome of the hives was recovered/resolved.   It was unknown if the reporter considered the hives to be related to Shingrix.     Additional Information: GSK receipt date: 17-Feb-2023 Reporter's comment: The patient had the reaction to her first Shingrix dose in left arm and 6 to 7 days after the shot had large (big) hives on the inside of both arms.  The pharmacist told the patient to go to urgent care (it was the weekend) because it was well past the 2 to 3 days of expected side effects. The patient was put on a steroid and given some cream and was fine after a few days. Lot and expiry date were unknown. The patient asked that she should get the second dose. One pharmacist told the patient to get the second dose. The physician was unsure.
This is a spontaneous report received from noncontactable consumer or other non-HCP. A 60-year-old male patient received unknown dose number of BNT162B2 (Comirnaty, batch/lot# unknown), single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. Vaccination history included unknown dose number of the COVID-19 vaccine (manufacturer unknown), for COVID-19 immunization. The patient reported immunisation/booster, pyrexia/fever and chills (non-serious), all with outcome of unknown. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
Stinging sensation after injection and sweet taste in my mouth.  Around 9:00 PM I had a low temp of 99.5 F and full body chills.  By 11 PM was running a 101.8 F fever.  Took some over the counter cold medicine to reduce the fever.  By 7:20 am on 4/8/21 temp was 98.9 F, but having trouble concentrating/ focusing and feel fatigued just getting up and moving to another location.
This spontaneous report was received from an office manager and refers to a 4-year-old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 08-DEC-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
expired dose of INFANRIX was administered to an adult patient; expired dose of INFANRIX was administered to an adult patient today.; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 31-year-old female patient who received DTPa (Infanrix) (batch number 23T73, expiry date 30-APR-2023) for prophylaxis.   On 28-JUN-2023, the patient received Infanrix. On 28-JUN-2023, an unknown time after receiving Infanrix, the patient experienced expired vaccine used (Verbatim: expired dose of INFANRIX was administered to an adult patient) and adult use of a child product (Verbatim: expired dose of INFANRIX was administered to an adult patient today.). The outcome of the expired vaccine used and adult use of a child product were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 28-JUN-2023 Nurse reported that an expired dose of Infanrix was administered to an adult patient, which led to expired vaccine used and adult use of a child product. The reporter consented to follow up.
About an hour after the shot the front of my face felt numb.  It lasted about 20 minutes.  Very disconcerting.  Tomorrow is my second shot and I?m scared.
pt recvd vax 9AUG94, fainted no injury-sent to hosp ER secondary to stay pt recovered & discharged;
Fever started and lasted for 4 days. The peak (tested) was 104.4.  Took to a different doc. and learned she also got an ear infection, something she doesn't get. Doc said they OFTEN SEE IT IN THOSE WITH THE PCV13 Shot! This turn into a double eye infection and she also got a full body rash and return of fever.
Patient had a rash that appeared up & down entire left arm 1 -2 hrs after vaccine was given. She also said she had extreme chills that night as well.
On same day of the first Pfizer COVID-19 vaccine, patient developed left facial numbness, left arm and left leg weakness with difficulty negotiating stairs, and left arm > left leg involuntary muscle "spasms."  Symptoms have improved, but not totally gone away. Patient also complained of severe "brain fog," and severe left arm tenderness after Pfizer vaccine.
WITHIN 6 HOURS OF RECEIVING VACCINE, PATIENT EXPERIENCED BILATERAL SHOULDER/ARM PAIN, CHILLS, FEVER > 100F, SHORTNESS OF BREATH, AND WEAKNESS - SYMPTOMS LASTED 8 HOURS THEN RESOLVED